Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Business
Boehringer Ingelheim Will Acquire Actimis
June 23, 2008
| A version of this story appeared in
Volume 86, Issue 25
Germany's Boehringer Ingelheim has agreed to acquire Actimis Pharmaceuticals, a privately held biotech company in San Diego. Spun off from Bayer in 2004, Actimis focuses on small-molecule drugs for respiratory, inflammatory, and autoimmune diseases. BI will acquire the company through a structured buyout, purchasing shares according to development milestones reached by Actimis' lead compound, called AP768, for treating asthma. If AP768, now in Phase I clinical trials, successfully advances into Phase III, BI will own 100% of Actimis' shares in a deal totaling $515 million.
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X